MA42654A - Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt - Google Patents
Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou namptInfo
- Publication number
- MA42654A MA42654A MA042654A MA42654A MA42654A MA 42654 A MA42654 A MA 42654A MA 042654 A MA042654 A MA 042654A MA 42654 A MA42654 A MA 42654A MA 42654 A MA42654 A MA 42654A
- Authority
- MA
- Morocco
- Prior art keywords
- pyridin
- acrylamide
- nampt
- pak
- modulators
- Prior art date
Links
- SAUZERSNFCTTSP-ONEGZZNKSA-N (e)-3-pyridin-3-ylprop-2-enamide Chemical compound NC(=O)\C=C\C1=CC=CN=C1 SAUZERSNFCTTSP-ONEGZZNKSA-N 0.000 title 1
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 title 1
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 title 1
- RMJWTHQXDHWUKO-UHFFFAOYSA-N n-pyridin-3-ylprop-2-enamide Chemical compound C=CC(=O)NC1=CC=CN=C1 RMJWTHQXDHWUKO-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205964P | 2015-08-17 | 2015-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42654A true MA42654A (fr) | 2018-06-27 |
Family
ID=56799625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042654A MA42654A (fr) | 2015-08-17 | 2016-08-17 | Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190218207A1 (fr) |
| EP (1) | EP3337796A1 (fr) |
| MA (1) | MA42654A (fr) |
| WO (1) | WO2017031213A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108440515B (zh) | 2013-07-03 | 2022-05-03 | 卡尔约药物治疗公司 | 取代的苯并呋喃基和苯并噁唑基化合物及其用途 |
| US9994558B2 (en) | 2013-09-20 | 2018-06-12 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| EP3337797A1 (fr) | 2015-08-18 | 2018-06-27 | Karyopharm Therapeutics, Inc. | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) acrylamide pour le traitement du cancer |
| US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| WO2018191747A1 (fr) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions et procédés pour le traitement de l'hypertension pulmonaire |
| ES2957464T3 (es) * | 2017-04-14 | 2024-01-19 | Univ Arizona | Composiciones y métodos para tratar fibrosis pulmonar |
| US11498903B2 (en) | 2017-08-17 | 2022-11-15 | Bristol-Myers Squibb Company | 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases |
| CN111205232B (zh) * | 2020-02-26 | 2022-07-01 | 浙江天宇药业股份有限公司 | 一种替格瑞洛中间体的合成方法 |
| CN117624088A (zh) * | 2023-12-06 | 2024-03-01 | 中科国生(杭州)科技有限公司 | 一种氢化制备2,5-呋喃二甲胺的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108440515B (zh) * | 2013-07-03 | 2022-05-03 | 卡尔约药物治疗公司 | 取代的苯并呋喃基和苯并噁唑基化合物及其用途 |
| US9994558B2 (en) * | 2013-09-20 | 2018-06-12 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
-
2016
- 2016-08-17 US US15/752,542 patent/US20190218207A1/en not_active Abandoned
- 2016-08-17 MA MA042654A patent/MA42654A/fr unknown
- 2016-08-17 EP EP16756922.7A patent/EP3337796A1/fr not_active Withdrawn
- 2016-08-17 WO PCT/US2016/047358 patent/WO2017031213A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017031213A1 (fr) | 2017-02-23 |
| US20190218207A1 (en) | 2019-07-18 |
| EP3337796A1 (fr) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42654A (fr) | Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt | |
| IL283582A (en) | Modulators of ror-gamma | |
| MA50014A (fr) | Modulateurs de k-ras | |
| EP3490565A4 (fr) | Modulateurs de récepteurs de chimiokine et leurs utilisations | |
| EP3353328A4 (fr) | Modulateurs de l'expression de kras | |
| MA55046A (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| LT3440076T (lt) | Heterocikliniai amidai, naudingi kaip baltymų moduliatoriai | |
| MA44075A (fr) | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 | |
| EP3356381A4 (fr) | Dérivés nucléotidiques et leurs méthodes d'utilisation | |
| MA55328A (fr) | Modulateurs de ror-gamma | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
| PT3160964T (pt) | Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos | |
| EP3450460A4 (fr) | Conjugué de liaison multi-spécifique, compositions pharmaceutiques associées et utilisation | |
| PT3426251T (pt) | Métodos de tratamento da depressão utilizando antagonistas dos recetores de orexina-2 | |
| LT3294713T (lt) | Pakeisti tetrahidrokvinoliniai junginiai, kaip ror gama moduliatoriai | |
| LT3319963T (lt) | Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas | |
| EP3580223A4 (fr) | Modulateurs du récepteur des strogènes de benzothiophène | |
| EP3654987A4 (fr) | Utilisation de dérivés aminoalkylbenzothiazépine | |
| MA40759A (fr) | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation | |
| IL255185A0 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto | |
| LT3685847T (lt) | Komplemento aktyvumo moduliatoriai | |
| EP3353303A4 (fr) | Compositions et méthodes de modulation de l'expression de l'ataxine 3 | |
| HUE056613T2 (hu) | Komplementaktivitás modulátorai |